TBRG4 identified as marker of poor survival and driver of tumor progression in lung adenocarcinoma

Most people over 50 were already adults when the Americans with Disabilities Act took effect in 1992 and transformed the rights of people with physical and mental conditions.

Researchers at the Francis Crick Institute have found that hunger can make virgin female mice aggressive towards pups, but only in certain hormonal states. These mice would usually ignore other females' pups or show parent-like caring behavior.

A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes—a finding that could guide treatment decisions and help many people avoid lymph node biopsy surgery. The study results are published in JAMA Surgery.

Researchers have identified factors associated with survival for patients initially diagnosed with metastatic breast cancer who were seen at UT Southwestern Medical Center and its affiliated sites. Their findings, published in Communications Medicine, list certain demographic and clinical characteristics to consider among the regional population when formulating treatment plans for individual patients.

The price tag of health insurance from employers keeps getting bigger across the U.S., and the increases this year are fueling concerns over medical spending across all health insurance markets.

Cellular changes that appear during melanoma and lead to treatment resistance can be reversed with drugs—potentially opening the door to new or more effective treatments for the deadly disease, according to new Cornell research.

With ads everywhere for pro- or pre-biotic foods and supplements, most people are familiar with the gut microbiome—the trillions of bacteria, fungi, and viruses that colonize our digestive tract—and the idea that keeping our gut microbiome healthy improves our overall health. But other areas of our bodies harbor their own unique microbiomes as well, and researchers are now starting to explore the role these microbial ecosystems play in health and disease.

A comprehensive meta-analysis in depression and mortality, led by the Department of Psychiatry at the School of Clinical Medicine, LKS Faculty of Medicine at the University of Hong Kong (HKUMed), has found that people with depression have twice the risk of death than those without depression, and a nearly 10-fold increased risk of suicide. However, timely and effective treatment can significantly reduce these risks and improve survival rates.

The number of people receiving treatment for cancer has risen dramatically in the last decade in many African countries. For example, 10 years ago in Ethiopia and Kenya, cancer care was available to only a few thousand patients per year in a few hospitals. Today, over 75,000 people receive cancer treatment each year in each of these countries.

About 50% of menopausal women experience genitourinary syndrome of menopause (GSM) that involves changes to the genitals, including the vagina, urethra and bladder. When estrogen levels drop during menopause, it can cause the GSM symptoms of vaginal dryness, itching, burning, frequent urinary tract infections and pain during sex. Replenishing the hormone through vaginal estrogen is an effective GSM treatment. But many breast cancer survivors either can't or don't want to use estrogen.

The number of people living with dementia worldwide was estimated at 57 million in 2021 with nearly 10 million new cases recorded each year. In the U.S., dementia impacts more than 6 million lives, and the number of new cases is expected to double over the next few decades, according to a 2025 study. Despite advancements in the field, a full understanding of disease-causing mechanisms is still lacking.

Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features linked to KRAS inhibitor resistance, according to data from a phase I trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22-26.

Researchers led by investigators at Mass General Brigham and Massachusetts Institute of Technology have validated an ingestible capsule in preclinical models for the diagnosis of acute mesenteric ischemia, a condition caused by blocked or reduced blood flow to the intestines. The research is published in Science Robotics.

Nearly one-third of people with type 2 diabetes (T2D) in an Indian cohort have achieved remission through an intensive lifestyle intervention program, according to a study published in PLOS One by Pramod Tripathi of the Freedom from Diabetes Clinic & Diabetes Research Foundation, India, and colleagues.

Feeding in mammals is controlled by a complex neural system. Although several key neural pathways related to total calorie intake have been extensively studied, it is still unclear how food choices are regulated and how they influence overall feeding behavior.

Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, according to results from the phase II eNRGy clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets, held October 22–26.

Ocular fluids provide a window into the health of the eye and the development of various pathologies. However, their study usually involves invasive techniques. "A wide range of eye diseases are being investigated, but the methods for obtaining aqueous humor and vitreous humor, the fluids inside the eye, are highly invasive, which limits their applicability in routine clinical practice," explains Marta San Roque, Ph.D. student in the Innovation in Vesicles and Cells for Application in Therapy (IVECAT) Group at the Germans Trias i Pujol Research Institute (IGTP).

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce anticancer responses in patients with extensive-stage small cell lung cancer (ES-SCLC) according to results from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22-26.